4,746 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by Headlands Technologies LLC

Headlands Technologies LLC acquired a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 4,746 shares of the company’s stock, valued at approximately $171,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SWTX. Pictet Asset Management Holding SA boosted its position in shares of SpringWorks Therapeutics by 24.2% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,391,412 shares of the company’s stock valued at $86,402,000 after acquiring an additional 465,494 shares during the last quarter. Principal Financial Group Inc. raised its stake in SpringWorks Therapeutics by 102.5% in the third quarter. Principal Financial Group Inc. now owns 918,445 shares of the company’s stock valued at $29,427,000 after purchasing an additional 464,903 shares in the last quarter. Vanguard Group Inc. lifted its position in SpringWorks Therapeutics by 6.6% during the fourth quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company’s stock valued at $258,650,000 after purchasing an additional 445,593 shares during the last quarter. Raymond James Financial Inc. purchased a new position in SpringWorks Therapeutics in the 4th quarter worth approximately $10,527,000. Finally, Norges Bank bought a new position in shares of SpringWorks Therapeutics in the 4th quarter worth $6,738,000.

Insider Transactions at SpringWorks Therapeutics

In related news, COO Badreddin Edris sold 30,000 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $53.13, for a total transaction of $1,593,900.00. Following the sale, the chief operating officer now owns 189,712 shares of the company’s stock, valued at $10,079,398.56. The trade was a 13.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Bhavesh Ashar sold 1,016 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the completion of the sale, the insider now owns 62,053 shares in the company, valued at $3,797,023.07. The trade was a 1.61 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 440,766 shares of company stock valued at $24,402,956. Corporate insiders own 7.61% of the company’s stock.

SpringWorks Therapeutics Stock Down 9.2 %

NASDAQ:SWTX opened at $39.09 on Friday. The firm has a market capitalization of $2.93 billion, a P/E ratio of -11.23 and a beta of 0.79. The company has a fifty day moving average of $48.71 and a 200 day moving average of $39.97. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). The business had revenue of $61.55 million during the quarter, compared to the consensus estimate of $60.53 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. As a group, analysts anticipate that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on SWTX shares. Evercore ISI lifted their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Wedbush reiterated an “outperform” rating and issued a $81.00 price objective on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. Guggenheim decreased their price objective on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $73.20.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.